Beyond Capital: Why Foreign Startups Are Building Their Next Chapter in Abu Dhabi

Abu Dhabi is rapidly strengthening its position on the global startup map, attracting international companies that are looking beyond traditional innovation hubs for the right environment to scale. For founders, the appeal is increasingly about more than access to capital. It is about finding an ecosystem where funding, talent, infrastructure, regulation, research capabilities and commercial opportunities can work together.

The emirate was ranked among the world’s Top 50 emerging startup ecosystems in the Global Startup Ecosystem Report 2026, placing it in the #41–50 range globally, up from #51–60 the previous year. Its ecosystem value reached US$73.4 billion, representing a 3,057% increase over the H2 2023–2025 baseline period. Growth has been particularly visible across sectors including artificial intelligence, fintech, climate technology, Web3 and digital assets.

For foreign founders, however, rankings tell only part of the story. The experiences of startups operating in different industries demonstrate why Abu Dhabi is becoming an increasingly attractive base for companies seeking to move from early-stage ambition to execution.

Three companies in particular—nature-tech startup Archireef, biotechnology company Vivan Therapeutics, and fintech platform Inovat—offer a useful look at how the ecosystem works in practice.

Archireef: Building Nature-Tech Through Policy and Infrastructure

Founded in Hong Kong in 2020 by Vriko Yu, CEO, and Deniz Tekerek, CCO, Archireef develops nature-based technologies designed to support marine biodiversity restoration. The company established its Abu Dhabi presence in 2022 and has since expanded into Singapore and Saudi Arabia.

For Archireef, Abu Dhabi’s biggest advantage has been the ability to bring government institutions, infrastructure stakeholders, environmental authorities and private capital into the same ecosystem.

Yu says the company was attracted by an environment where infrastructure investment, environmental regulation and capital could be brought into the same conversation. That proximity, she argues, can help science-driven companies move from introductions and pilot projects to actual deployment more efficiently.

Archireef entered Abu Dhabi with support from ADQ, a sovereign investor focused on critical infrastructure and global supply chains, as well as Hub71, Abu Dhabi’s global technology ecosystem for startups. Early engagement with the Environment Agency – Abu Dhabi (EAD) also helped the company understand the market and establish relationships with relevant stakeholders.

The company’s work aligns closely with Abu Dhabi’s growing focus on environmental sustainability. Archireef has partnered with EAD to advance coral reef restoration and marine biodiversity protection using its 3D-printed eco-engineering solutions.

For a nature-tech company, this alignment between policy and commercial projects is particularly important. Rather than treating biodiversity as an afterthought, Abu Dhabi provides opportunities to incorporate ecological considerations into projects from the beginning.

Archireef also established an eco-engineering factory at Khalifa Economic Zones Abu Dhabi (KEZAD) while setting up its operational headquarters at Abu Dhabi Global Market (ADGM). This structure enabled the company to manufacture locally while maintaining a base within one of the region’s major international financial centers.

Access to industrial talent has also proved valuable. Yu highlights Abu Dhabi’s ability to provide people with experience in working with materials such as clay, sand and oyster shells, which are relevant to the company’s manufacturing and eco-engineering activities.

Funding remains challenging, as it does for startups globally. Archireef received early backing from an Abu Dhabi-based sovereign wealth fund while also raising from venture capital investors in Norway and Singapore.

For Yu, however, the objective has consistently been revenue rather than simply raising successive funding rounds. The company’s experience suggests that strategic investors capable of contributing commercial relationships and expertise can be more valuable than capital alone.

Vivan Therapeutics: Abu Dhabi’s Growing Deep-Tech Healthcare Opportunity

The story of Vivan Therapeutics illustrates another dimension of Abu Dhabi’s startup ecosystem: its growing healthcare and deep-tech infrastructure.

Founded in the UK by Laura Towart, Vivan Therapeutics focuses on personalized cancer treatment by identifying drug combinations based on the genetic characteristics of an individual patient’s tumor.

Towart had previously lived and worked in the GCC for six years, giving her familiarity with the region and an established network. However, she identifies Hub71 as one of the key factors behind the company’s decision to establish a presence in Abu Dhabi.

The company established its regional entity at ADGM in 2025. According to Towart, the process was fast and straightforward, while the ability to connect directly with clinicians, investors and government officials offered an important advantage compared with larger markets.

Abu Dhabi’s healthcare infrastructure also aligned with Vivan’s requirements. The emirate offers access to clinical partners, research institutions, capital and a regulatory environment that can support deep-tech healthcare companies.

The company is currently developing TuMatch, an AI-powered clinical decision-support engine designed to help identify potential treatment options for cancer patients. The technology is intended to assist clinicians, pharmaceutical companies and patients by using tumor-specific information to identify potential treatment combinations.

Vivan has collaborated with Burjeel Cancer Institute on a prospective clinical registration study for TuMatch, focused on personalized colorectal cancer treatment guidance. The company has also been engaging with healthcare providers, including Cleveland Clinic, as it develops its regional commercial presence.

The company’s relationships with institutions such as Khalifa University could further expand its access to tumor-genomics research, machine learning, computing expertise and laboratory capabilities.

Vivan is also seeking growth funding to establish a robotics-driven R&D center in Masdar City. The proposed facility would generate local datasets across cancer, diabetes and other genetic diseases, supporting future drug-development programs.

The company’s next phase will focus on scaling its clinical and institutional momentum, beginning with the TuMatch registration study and progressing toward regulatory approval and reimbursement. Vivan is also exploring applications across gastrointestinal cancers, lung cancer, glioblastoma and other solid tumors, alongside potential applications involving diabetes.

For Towart, speed will be critical. Faster approvals, partnerships and deployment could allow patients to benefit from the technology sooner.

Inovat: Using Abu Dhabi as a Global Travel-Fintech Base

For London-founded fintech company Inovat, Abu Dhabi represents something slightly different: a strategic bridge connecting financial institutions, travel businesses and international markets.

Founded by Ilya Melkumov, Sofiia Baranova and Igor Titov, Inovat provides infrastructure that enables banks, insurers and travel companies to offer digital VAT refunds to international travelers.

The company established its Abu Dhabi base in 2023 and raised its first financing round there.

Its founders found that Hub71 helped establish direct connections with investors, banks, potential partners and professional advisers. At the same time, operating across fintech, travel and tax infrastructure requires careful attention to licensing, banking and compliance.

Abu Dhabi’s geographic position between Europe and Asia is particularly relevant to Inovat because its business serves financial institutions and travelers across both regions.

The company has found venture funds, strategic investors and family offices to be among its most accessible sources of capital. However, Melkumov emphasizes that fundraising still depends on demonstrating execution, traction, sound unit economics and a credible regulatory strategy.

For Inovat, evidence of live operations, partnerships with financial institutions and measurable transaction volumes has been central to building investor confidence.

The company’s long-term ambition extends well beyond the UAE. It aims to build banking and fintech partnerships throughout the GCC while continuing to expand across Europe and Asia.

Its objective is to integrate VAT-refund infrastructure directly into banking, insurance and travel platforms, enabling travelers to access services through providers they already know and trust.

Melkumov believes deeper relationships with regional banks, payment companies and government stakeholders would further accelerate the company’s expansion.

Abu Dhabi’s Bigger Startup Proposition

Although Archireef, Vivan Therapeutics and Inovat operate in completely different industries, their experiences reveal several common characteristics of Abu Dhabi’s emerging startup ecosystem.

The first is institutional connectivity. Startups can access government bodies, investors, research institutions, corporates and other stakeholders through a relatively concentrated ecosystem.

The second is infrastructure. For companies working in manufacturing, healthcare, artificial intelligence or financial technology, the ability to access physical and institutional infrastructure can be as important as venture capital.

The third is strategic alignment. Abu Dhabi’s economic diversification agenda increasingly prioritizes sectors such as AI, healthcare, sustainability and advanced technology. Startups whose business models contribute to these priorities can potentially find stronger opportunities for collaboration.

The fourth is market access. The emirate can function not only as a domestic market but also as a gateway to the wider GCC, Asia and Europe.

The fifth is long-term relationships. Inovat’s experience particularly highlights that founders should not approach Abu Dhabi simply as a place to incorporate a company. Building relationships with investors, government entities, banks, research institutions and commercial partners is central to successful expansion.

Why Foreign Founders Are Looking Beyond Capital

The broader lesson from these three startups is that the definition of a startup ecosystem is changing.

Capital remains essential, but companies operating in increasingly complex sectors require much more. A biotech company needs clinical infrastructure and regulatory pathways. A nature-tech company needs access to projects, environmental institutions and manufacturing capabilities. A fintech company needs banking relationships, regulatory clarity and enterprise customers.

Abu Dhabi’s emerging proposition is to bring many of these requirements together.

For foreign startups, the opportunity therefore lies in using the emirate not merely as a headquarters location, but as a platform for experimentation, partnerships, commercialization and international expansion.

Programs such as Hub71 can help companies access investors, incentives and mentorship, while ADGM and KEZAD provide different forms of business and industrial infrastructure. Institutions such as EAD, healthcare providers and universities can further connect startups with real-world applications and research opportunities.

At the same time, founders should approach the market with realistic expectations. Abu Dhabi does not eliminate the challenges associated with fundraising, regulation or enterprise sales. Investors still demand evidence of traction, strong economics and credible strategies, while regulated industries require careful planning.

For founders entering the emirate, the strongest strategy may therefore be to arrive with a working product, a clear commercial proposition and a specific understanding of how the company can contribute to Abu Dhabi’s strategic priorities.

From Abu Dhabi to Global Markets

The journeys of Archireef, Vivan Therapeutics and Inovat suggest that Abu Dhabi’s competitive advantage may ultimately be its ability to connect different parts of the innovation economy.

A nature-tech company can combine environmental policy with manufacturing and infrastructure. A healthcare startup can connect AI with clinical research and pharmaceutical development. A fintech company can use Abu Dhabi’s position to connect financial institutions and travelers across multiple regions.

This creates an ecosystem in which the value of being in Abu Dhabi extends beyond the local market.

As the emirate continues investing in technology, healthcare, sustainability, financial services and economic diversification, its ability to connect international founders with capital, talent, institutions and markets could become one of its strongest advantages.

For foreign startups, the message is increasingly clear: Abu Dhabi is positioning itself not simply as a place to raise money or register a company, but as a place where ambitious businesses can build, test, commercialize and scale.